| 产品名称 | CI 994 - PD 123654 | Tacedinaline |
| 产品货号 | Axon 2014 CAS [112522-64-2] MF C15H15N3O2MW 269.30 Purity: 98% Soluble in DMSO Description Orally bioavailable histone deacetylase (HDAC) inhibitor that causes histone hyperacetylation in living cells. CI-994 inhibited HDAC1 and HDAC2 in a concentration-dependent fashion; mediates G1 cell cycle arrest, inhibits proliferation and induces apoptosis in vitro and in vivo References Certificates Categories Extra info AG Kraker et al. Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. Mol. Cancer Ther. 2003, (4), 401-408. M Loprevite et al. In Vitro Study of CI-994, a Histone Deacetylase Inhibitor, in Non-Small Cell Lung Cancer Cell Lines. Oncol. Res. Feat. Preclin. Clin. Cancer Ther. 2005, 15(1), 39-48. Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Cycle Regulation Cell Signaling & Oncology Epigenetics DNA-damage Response EC 3.5.1.98 HDAC Pfizer Licensed Products HDAC inhibitor that causes histone hyperacetylation in living cells Chemical name 4-acetamido-N-(2-aminophenyl)benzamide Source information Pfizer compound; Sold for research purposes under agreement from Pfizer Inc. Parent CAS No. [112522-64-2] Order Size Unit Price Stock 10 mg €70.00 In Stock |
| 产品价格 | 现货询价，电话：010-67529703 |
| 产品规格 | |
| 产品品牌 | axonmedchem |
| 产品概述 | |
| 产品详情 |
CI 994 - PD 123654 | TacedinalineAxon 2014 CAS [112522-64-2] MF C15H15N3O2
Description
Orally bioavailable histone deacetylase (HDAC) inhibitor that causes histone hyperacetylation in living cells. CI-994 inhibited HDAC1 and HDAC2 in a concentration-dependent fashion; mediates G1 cell cycle arrest, inhibits proliferation and induces apoptosis in vitro and in vivo
HDAC inhibitor that causes histone hyperacetylation in living cells
Chemical name4-acetamido-N-(2-aminophenyl)benzamide Source informationPfizer compound; Sold for research purposes under agreement from Pfizer Inc.Parent CAS No.[112522-64-2] |
| 产品资料 |
